Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance.
about
Risk assessment in the prevention of cardiovascular disease in low-resource settingsCardiovascular riskNon-alcoholic fatty liver disease: what has changed in the treatment since the beginning?Big Data and Health Economics: Strengths, Weaknesses, Opportunities and Threats.Screening strategies for cardiovascular disease in asymptomatic adults.Myopathy in Patients Taking Atorvastatin: A Pilot Study.An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort studyPrimary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.Prevention of Decline in Cognition after Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids.Estimation of 10-Year Risk of Coronary Heart Disease in Nepalese Patients with Type 2 Diabetes: Framingham Versus United Kingdom Prospective Diabetes StudyThe case for more intensive use of statins.C-reactive protein, fibrinogen, and cardiovascular disease prediction.Assessment of cardiovascular disease risk in South asian populationsAn independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study.Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.Multimorbidity's research challenges and priorities from a clinical perspective: the case of 'Mr Curran'.How close are we to implementing a genetic risk score for coronary heart disease?Laboratory-based and office-based risk scores and charts to predict 10-year risk of cardiovascular disease in 182 countries: a pooled analysis of prospective cohorts and health surveys.Esophageal cancer: The latest on chemoprevention and state of the art therapies.Targeted case finding in the prevention of cardiovascular disease: a stepped wedge cluster randomised controlled trial.Ethnicity and risk of cardiovascular disease (CVD): 4.8 year follow-up of patients with type 2 diabetes living in Scotland.Cardiovascular risk tables.NICE on lipid modification: NICE's simplified approach to lipids will not work.NICE on lipid modification: NICE has overestimated cardiovascular risk.Gastrointestinal effects of eating quinoa (Chenopodium quinoa Willd.) in celiac patients.The challenge of cardiovascular prevention in primary care: implications of a European observational study in 8928 patients at different risk levels.PARS risk charts: A 10-year study of risk assessment for cardiovascular diseases in Eastern Mediterranean Region.Cost-effectiveness of noninvasive central blood pressure monitoring in the diagnosis of hypertension.
P2860
Q26744435-747E1E53-4E44-473A-9681-1EE8B51A3863Q26825634-FE348442-6904-4744-89D7-37FF61507A2FQ26829503-7DF43935-2A6C-430E-83C1-172F8427C7A2Q30975567-EE13B946-B160-4ACF-879E-323938B73101Q33704011-96CFA45C-029A-4A2C-8F62-EE3557DB2E96Q33815469-AA8A9706-77A9-4822-8F4F-872A1D7AD524Q33848884-23E4AAA8-624C-419C-9406-DC86CCC6340EQ33972551-F4893000-371F-46A6-A6A9-FA54EB1B6D23Q34465274-8F506AA8-625B-45FF-AE38-88F7A344C89CQ36032312-2F2F9ECF-B717-484C-AFB9-56CDFCBA476BQ36515517-33129608-FECC-4408-AC94-F16DF49B0866Q37021409-E189CA17-0C8D-421A-B5F0-804A3120CF92Q37218645-A13FEB35-D8B9-4F18-99FF-5D9F148B46AEQ37272230-07598EE8-32D8-4352-99DB-A18D2595CB7AQ38011204-64E1A3C1-7DB2-4ACE-95CD-734C3336D61CQ38155542-58A23F66-F831-4CFB-BCED-CA12E0A4E828Q38620513-4E7B74F8-3868-42B5-8699-DE071D690DAEQ38851422-6FBEA89C-EC46-43AD-A4AD-D0EDC651B8F4Q38938101-30E4ECF1-D021-44E4-81AC-16E244451F94Q40397890-B07370EB-CF34-44AE-A1AF-C6695EEBC045Q41452713-1B2693C4-D14E-4D7A-AB41-EFF3DB939178Q43077620-4DAA7A95-3974-457B-A76A-1B9DCF1DC6DAQ43262080-56E949A5-8380-4B89-A6DE-D61AD7752DE0Q43262142-9ABA9717-168A-4606-91A0-2CF2AE9AB8C2Q46154813-D3654F9F-754C-49CD-A798-31FAFCC38210Q46869790-0B6D59F6-F85E-4045-B770-E0201C5AE7D3Q47133024-5A5894B6-7315-4E28-A244-C3A78B2EDABEQ48168966-ED2DC30F-6A96-4F63-A5FC-248503CF4705
P2860
Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Risk assessment and lipid modi ...... ase: summary of NICE guidance.
@ast
Risk assessment and lipid modi ...... ase: summary of NICE guidance.
@en
type
label
Risk assessment and lipid modi ...... ase: summary of NICE guidance.
@ast
Risk assessment and lipid modi ...... ase: summary of NICE guidance.
@en
prefLabel
Risk assessment and lipid modi ...... ase: summary of NICE guidance.
@ast
Risk assessment and lipid modi ...... ase: summary of NICE guidance.
@en
P2093
P1433
P1476
Risk assessment and lipid modi ...... ase: summary of NICE guidance.
@en
P2093
Angela Cooper
Guideline Development Group
Norma O'Flynn
P304
P356
10.1136/BMJ.39554.624086.AD
P407
P577
2008-05-01T00:00:00Z